Providing patients with a new way to benefit from naltrexone
  • Libero’s purpose is to bring a new wave of transdermal treatments for numerous chronic conditions that have been shown to benefit from opioid receptor antagonism
  • Enabling stable, sustained plasma levels, drug delivery via a transdermal patch is an ideal treatment modality for many chronic conditions
  • The scale of unmet need and potential of Libero’s lead medicine led to the National Institute of Drug Abuse (NIDA) in the US awarding Libero a 5 year development grant to bring it to market
    •

    Benefits of transdermal vs daily oral delivery

    In the case of oral naltrexone, spikes in plasma concentration of the primary metabolite β-Naltrexol are also seen, increasing the risk of adverse effects. This is not expected with transdermal use.

    Transdermal delivery

    Patient-friendly, sustained drug delivery

    Unmet need

    Targeting conditions with a large and growing unmet need

    Expedited regulatory pathway

    Leveraging established data on the compounds to reduce time needed to be clinic-ready

    Patent-protection

    Patented formulations specific to different indications